Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan.
HyStem kits are based on thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid.
This acquisition includes the transfer of technology, intellectual property, know-how and assets for the manufacturing and sale of HyStem® products for research and development purposes. ABM and LTC are working closely together to ensure an efficient and seamless handover of the manufacturing, testing and distribution of products to users of the HyStem® products.
ABM began providing and distributing HyStem® products on October 1, 2019. ABM plans to manufacture and supply the full product line including HyStem®, HyStem-C® and HyStem-HP® kits, as well as the individual kit components in bulk format.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"The HyStem® family of hyaluronan-based hydrogels is highly complementary and fits perfectly into our catalog of innovative 3D matrices and hydrogels,” David Bagley, President of Advanced BioMatrix, said. “This acquisition will further strengthen the Advanced BioMatrix position as an industry leader in extracellular matrices and provide a broader range of high-quality products to our customers. We are eager to work with each of our existing and new customers to ensure unparalleled level of product quality and supply."